The value of BCMA-targeting therapy in multiple myeloma: current applications and future outlooks
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, shares some insights into the use of BCMA-targeted therapy in multiple myeloma, commenting on the value of agents including ciltacabtagene autoleucel (cilta-cel), idecabtagene vicleucel (ide-cel), and teclistamab. The emergence of bispecific antibodies hopes to address a current challenge with CAR-T cell therapy: the lack of widespread availability to the global myeloma patient population, and Dr Ramasamy highlights the importance of international collaborations to address challenges and improve outcomes for patients. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
-
Category
No comments found